|New in PD and Genetics: The PIís Dr. Jeremy Nichols Gives Keynote Presentation|
|Published Tuesday, August 21, 2012|
New in PD and Genetics: The PIís Dr. Jeremy Nichols Gives Keynote Presentation
Jeremy Nichols, PhD, recently gave the keynote presentation at a PD Research Symposium in Boston entitled: After the Compound: Exploring the Consequences of LRRK2 Inhibition.
Dr. Nicholsí presentation was based on the work of the Nichols Laboratory at The Parkinsonís Institute and his collaborators at the Katholieke Universiteit Leuven, Belgium and at the National Institutes of Health. Specifically, Dr. Nichols spoke about new insights into the regulation of LRRK2 and potential consequences of using small molecule inhibitors against LRRK2.
The Symposium was sponsored by Life Technologies, a research partner of The Parkinsonís Institute, and hosted academic researchers and representatives of multiple pharmaceutical companies. Events such as this are important as it brings together research scientists in an open forum to help breakdown the walls that exist between academia/research institutions and the pharmaceutical industry.
The Nichols Lab focuses on understanding the molecular basis of Parkinsonís disease caused by the mutations in the LRRK2 gene. They are working to understand the role of LRRK2 in the mutated and unmutated state in order to facilitate novel therapeutic developments that can halt or prevent PD.
The Nichols Laboratory is led by Jeremy Nichols, PhD and other researchers include: Fred Elfman, PhD; Jing Zhao, PhD; April Reynolds-Bent, PhD; Elizabeth Doggett and Dongmei Hu.
Here is an excerpt of the Life Technologies Symposium publication which includes Dr. Nichols' presentation.
Here is the full Life Technologies Symposium publication.
The Parkinson's Institute and Clinical Center